AffloVest is a lung clearance therapy for patients with respiratory diseases such as chronic obstructive pulmonary disease (COPD).
“As we enter our 25th year in delivering high-quality, innovative medical devices to patients in underserved markets, we are seeing rapid growth in our market share in both respiratory and surgical devices. Based upon results to date, we are highly confident that 2017 will continue and even exceed this trend of increased sales growth across all of our product offerings,” H. David Shockley, Jr., CEO of International Biophysics, said in a press release.
AffloVest is the first portable, battery-operated, high frequency chest wall oscillation (HFCWO) vest to promote airway clearance and lung secretion mobilization in the treatment of respiratory diseases like COPD, bronchiectasis, and cystic fibrosis (CF). The device applies vibrations at different frequencies to the chest wall via a wearable vest; such rapid and repeated pulses of positive air pressure gently oscillate the chest to facilitate mucus clearance.
The AffloVest, according to International Biophysics, incorporates state-of-the-art technology to feature eight built-in oscillating modules that allow for freedom of movement to do different kinds of daily activities, like going for a walk, doing chores around the house, or just relaxing on the couch. The system has targeted motors that can be directed at specific lobes or chest wall regions with different intensity levels.
“Through our sales and marketing efforts, we are building awareness for the AffloVest in the COPD patient population for bronchiectasis. We are pleased to see robust returns on our investments in infrastructure by moving production of the AffloVest from overseas to the United States and in growing our sales team here,” Shockley added.
International Biophysics showcased the AffloVest and the company’s latest achievements at the Medtrade Conference, which took place at the Mandalay Bay Convention Center in Las Vegas, Feb. 27-28.
Treatment with AffloVest requires a doctor’s prescription for HFCWO. The company has received clearance for U.S. market availability by the U.S. Food and Drug Administration (FDA), and the treatment is approved for Medicare and private health insurance reimbursement.